Improved long-term survival in multiple myeloma up to the age of 80 years

Leukemia

Volumn 28, Issue 6, 2014, Pages 1346-1348

  Kristinsson, S Y ^a,b   Anderson, W F ^c   Landgren, O ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ICELAND   (Iceland)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BORTEZOMIB; CARFILZOMIB; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; PREDNISONE; STEROID;

ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; GROUPS BY AGE; HEALTH CARE QUALITY; HUMAN; LETTER; LEUKEMIA REMISSION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLE MYELOMA; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STEROID THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; VERY ELDERLY; ADOLESCENT; AGE; CANCER PATIENT; CANCER REGRESSION; CHILD; FOLLOW UP;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SEER PROGRAM; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 84902106203     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.23     Document Type: Letter

References (17)

1. Socialstyrelsen. Cancer Incidence in Sweden 2006. Stockholm, Sweden 2007.
2. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: A population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007; 25: 1993-1999. (Pubitemid 46972782)
3. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R et al. Complete response correlates with long-Term progression-free and overall survival in elderly myeloma treated with novel agents: Analysis of 1175 patients. Blood 2011; 117: 3025-3031.
4. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
5. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132. (Pubitemid 350146107)
6. Turesson I, Kristinsson SY, Bjorkholm M, Landgren O. Clinical trials and populationbased studies to assess survival benefits in multiple myeloma: Welcome to the future! Blood 2011; e-pub ahead of print 9 November 2011; http://bloodjournal. hematologylibrary.org/content/118/12/3205/reply.
7. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: A population-based study. J Clin Oncol 2010; 28: 830-834.
8. Brenner H, Gondos A, Pulte D. Recent major improvement in long-Term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
9. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
10. Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY et al. Racial disparities in incidence and outcome in multiple myeloma: A populationbased study. Blood 2010; 116: 5501-5506.
11. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients. Leukemia 2013; e-pub ahead of print 25 October 2013; doi:10.1038/leu.2013.313.
12. Surveillance E. End Results (SEER) Programwww.seer.cancer.govSEER Stat Database: Incidence-SEER 9 Regs Research Data, Nov 2011 Sub (1973-2010) oKatrina/Rita Population Adjustment4-Linked To County Attributes-Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission.
13. Fritz AG. International Classification of Diseases for Oncology: ICD-O. 3rd edn. World Health Organization: Geneva, Switzerland, 2000, pp 240, vii.
14. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
15. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028. (Pubitemid 44395016)
16. Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012; 120: 1801-1809.
17. Landgren O, Korde N. Treating myeloma: The future is already here! Blood 2012; 120: 1754-1756.